Bentham Science Logo

Track Your Manuscript:


Recent Patents on Anti-Cancer Drug Discovery

Volume 16, 4 Issues, 2021
ISSN: 2212-3970 (Online)
ISSN: 1574-8928 (Print)
This journal supports open access

Call for Editors

Recent Patents on Anti-Cancer Drug Discovery is recruiting Editors in the following areas (and other important areas) of the Journal. If you are interested, then please submit your details for the Editor in Chief’s consideration below.

  1. Adenocarcinoma
  2. Adjuvant Therapy
  3. Angiogenesis and Cancer
  4. Antioxidant and Cancer
  5. Apoptosis
  6. Aptamers and Cancer
  7. Autophagy
  8. Breast Cancer
  9. Cancer and Nanomedicine
  10. Cancer Biomarker
  11. Cancer Epigenetics
  12. Cancer Signal Transduction
  13. Cancer Stem Cell
  14. Cancer Vaccines
  15. Carcinogenesis
  16. Chemotherapy and chemoresistance
  17. Circulating Tumor Cell
  18. Clinical Oncology
  19. Covid and Cancer
  20. Glioblastoma
  21. Gynecologic Oncology
  22. Hepatocellular Carcinoma
  23. Immunogenic Cancer Cell Death
  24. Immunotherapies
  25. Leukemia
  26. Lung Cancer
  27. Medical Oncology
  28. Mesenchymal Stromal Cells
  29. Monoclonal Antibodies
  30. Next-Generation Sequencing and Cancer
  31. Oncogenes
  32. Target Drug Delivery and Cancer
  33. Target Therapy and Cancer
  34. Transcriptomics and Cancer
  35. Tumor Microenvironment
  36. Tumor-Infiltrating

* If you are willing to become an Editor, in any other section (not listed above), which you feel is relevant to Journals' scope, then please inform us by choosing the “Others” option from the drop down list when you are filling the form below.

Responsibilities:
  1. Editors are responsible to contribute 1 thematic issue each year in a their area of interest. We expect to receive thematic issue proposals from section editors within 4 months of their appointment, a list of potential authors (with a respectable h-index) within 6 months and the complete thematic issue within 9 months.
  2. Editors are also expected to occasionally solicit/contribute review articles.
  3. Promote the thematic issue amongst the research community to increase its visibility
Selection Criteria:

Selection by the Editor-in-Chief will be based on, but not limited to, the following factors:

  • Interested candidates must at least hold a Doctorate degree
  • A broad and extensive knowledge of the field
  • Previous editorial experience would be desirable


Editor Details

* These fields are mandatory.








Editor-in-Chief

Zhe-Sheng (Jason) Chen
Institute for Biotechnology
College of Pharmacy and Health Sciences
St. John's University
New York, NY
(USA)
Biography
View Full Editorial Board

COPE Compliant

Cope Logo

Journal History

Recent Patents on Anti-Cancer Drug Discovery was launched in 2006. Prof. Zhe-Sheng (Jason) Chen serves as the Editor-in-Chief of the journal.

Advertisement

Oct-2021-ban

Related Journals

Related eBooks

eBooks Catalog